RHA Statement on FDA Inaction on Youth Vaping

In Illinois and across the nation, the surge in youth vaping isn’t just a matter of experimentation; it’s a public health crisis that demands immediate attention. Children are exposing themselves to harmful chemicals like nicotine and formaldehyde, which jeopardizes their developing bodies and increases the likelihood of addiction not just to nicotine, but to other substances as well.

At the heart of this crisis lies disposable, flavored e-cigarettes, the majority of which are manufactured overseas. While the FDA took a commendable step in 2020 by banning pod-based e-cigarettes, they neglected to impose restrictions on their disposable counterparts, creating a dangerous loophole. Consequently, more than 5,800 unique disposable products have flooded the market- a staggering 1,500% increase from early 2020. These products are designed to entice children with sweet, candy-like flavors, flashy packaging, and aggressive marketing on social media. It’s no surprise that 85% of youth e-cigarette users prefer flavored products, with fruit and candy options topping the list.

The harsh reality is that the majority of these products are being sold illegally, blatantly violating FDA regulations. The Food and Drug Administration must move to approve each e-cigarette product before they can be sold. These flashy, kid-friendly flavored products that are helping drive youth vaping rates should not be available for sale. The FDA must do its job, enforce existing regulations, and crackdown on the sale of illegal, flavored vapes that directly endanger American children. Thankfully, we have a U.S. Senator in Dick Durbin who has been pressuring the FDA to stop this illegal market and we commend him for his work. Yet, we still need more members of the community and other elected officials to address this issue before it’s too late.

We will keep you posted on the latest developments and please sign our action alert.


RHA Statement on the Introduction of ZYN to the US Market

This month, Phillip Morris International introduced ZYN, a nicotine pouch produced by Swedish Match, to the US market. This product is a small, occasionally flavored, pouch that is placed behind the lip to release nicotine to the user. Unfortunately, the product is being promoted to young American audiences through targeted social media campaigns, exposing yet another cohort of young people to the addictiveness of nicotine.

Nicotine is an addictive chemical found in e-cigs, cigarettes, and cigars. Research from the National Institutes of Health found that the health risks of using nicotine include everything from increased blood pressure to increased heart attack risk or even acute nicotine toxicity. According to the CDC, nicotine exposure in adolescence can hinder brain development.

ZYNs are “a pouch packed with problems [and] high levels of nicotine, said Senate Majority Leader Chuck Schumer in a statement on January 21, 2024. Sen. Schumer delivered “a warning to parents, because these nicotine pouches seem to lock their sights on young kids – teenagers, and even lower – and then use the social media to hook ’em.”

Respiratory Health Association supports tighter regulation by the Federal Trade Commission and the Food and Drug Administration of all nicotine products.

“The best way for a smoker to break their addiction to nicotine is to follow a proven successful quit smoking program,” said RHA President and CEO, Joel Africk. “Unfortunately, switching to other forms of nicotine just continues the addiction and makes it easier for someone to start smoking.”

For help quitting smoking, visit RespHealth.org/CourageToQuit. Courage to Quit® is an evidence-based group or individual tobacco treatment program for adults. It is the cessation component of RHA’s integrated tobacco intervention program. Courage to Quits effectiveness has been documented in the American Journal of Public Health and is based on the work of Andrea King, PhD, a faculty member at the University of Chicago and licensed psychologist with a research background in tobacco and other addictions.


About Respiratory Health Association

RHA has been a local public health leader in Chicago since 1906. RHA works to prevent lung disease, promote clean air, and help people live better through education, research, and policy change. To learn more, visit www.RespHealth.org.

COVID-19 and the Flu

As we enter flu season, it is more important than ever to get your flu shot this year. Below is information on the importance of getting your flu shot and COVID-19 vaccine, who should be getting these vaccinations, when and where you should get them.

Why is the flu shot so important this year?

The symptoms of flu and COVID-19 are very similar:

  • Fever
  • Cough/Sore throat
  • Headache
  • Muscle aches
  • Fatigue

Getting the flu can leave you more vulnerable to COVID-19, and those who are already at risk for getting respiratory diseases could face more severe cases. It is especially important to get the flu shot this year because if you do get sick with one of these lung illnesses this fall, it could help reduce the severity of your symptoms.

What are the benefits of getting the flu shot and the COVID-19 vaccine?

According to the Centers for Disease Control, there were 110,000-230,000 flu hospitalizations in 2023. The flu shot and COVID-19 vaccine can:

  • Protect you, your family, neighbors, and community
  • May help you avoid COVID-19 exposure from doctor offices or hospitals
  • Decreased severity of symptoms and lower hospitalization risk
  • Help hospital workers save resources

How does the flu shot work?

The flu vaccine introduces an inactivated or weak version of the virus to your body, which causes your immune system to produce protection against it. You may sometimes have mild symptoms after receiving the flu vaccine; this is your body developing its response to the inactivated or weakened virus. When you are actually exposed to the virus, your body can fight it off or reduce its impact so you only experience mild symptoms.

Who should get the flu shot?

Everyone over six months old should get the flu shot.

Who should get the COVID-19 vaccine?

Everyone aged 5 years or older should get the COVID-19 vaccine. As of September 2023, the CDC recommends the updated 2023-2024 Pfizer-BioNTech and Moderna COVID-19 Vaccines. It is especially important for high-risk groups to get vaccinated. These groups include:

  • Pregnant women
  • Older adults
  • Essential workers
  • Caretakers exposed to vulnerable groups
  • Those with underlying illnesses like asthma, heart disease, or COPD

When should you get the flu shot and COVID-19 vaccine?

Most drugstores in the U.S. now have the flu vaccine in stock. However, experts suggest waiting until September or October so the vaccine protection lasts the whole flu season. This is especially important for adults over 65 and those with compromised immune systems. There is a special flu vaccine for adults 65 years and older with a higher dosage that protects against four strains of the flu. For COVID-19, the vaccination is available year round. If you have had the virus, it is recommended to wait three months after infection to receive your vaccination. It is safe to receive both the flu shot and the COVID-19 vaccination at the same time. It is important to talk to your healthcare provider about the options that are available to you.

Where are these vaccines available?

Rite Aid, CVS, and Walgreens all have the vaccine in stock, and most other drugstores have begun offering the vaccine. Doctors’ offices also offer the vaccine but be sure to call your healthcare provider ahead of time to make sure they have the flu shot in stock. You can also visit vaccinefinder.org for more vaccine locations.

What is the cost?

For those with private insurance, Medicare, or Medicaid, the shot is usually free or comes with a low copayment. The COVID-19 vaccination is free with insurance. For those without insurance, the cost for the regular shot is $58.99 at Walgreens and $62.99 at CVS and Rite Aid. The COVID-19 vaccine is free with government assistance. The uninsured cost of the high-dose vaccine for those 65 and older is $106.99 at CVS and Rite Aid and $108.99 at Walgreens.

Evanston Limits the Sale of E-Cigarettes, Flavored Tobacco, and Synthetic Nicotine

Evanston has once again shown itself to be a leader in the state of Illinois by keeping its residents safe from the health impacts of consuming tobacco products. In a City Council meeting on November 27, the Evanston City Council voted 6-3 to pass an ordinance banning the sale of all flavored e-cigarettes and flavored tobacco products – including menthol cigarettes and synthetic nicotine. Respiratory Health Association applauds the Evanston City Council, as well as the residents, advocates, and organizations that supported the protective measure. The passage of this comprehensive ban and the resulting restriction of the sale of all flavored tobacco products, including menthol cigarettes, will help end the cycle of addiction and protect against the deadly impact of tobacco use.

“Thank you, Evanston City Council, for standing up to the tobacco industry and proposing this bold, lifesaving policy,” said Joel Africk, CEO and President of Respiratory Health Association.

State of Illinois First to Fund School Asthma Program – RESCUE Program Aims to Keep Kids with Asthma in School

September 5, 2023 – Chicago, IL – Respiratory Health Association (RHA) and Asthma and Allergy Foundation of America (AAFA) have launched the RESCUE Illinois Schools program. RESCUE, which stands for Resources for Every School Confronting Unexpected Emergencies, will serve over 3,000 schools in Illinois in its first year.

The purpose of the program is to provide asthma medication and training for schools to respond to asthma emergencies. Training will be provided to all Illinois school nurses and other school staff on how to respond to a student having an asthma episode during school hours. The goal is to keep students healthy, in class, and out of the emergency room.  While 17 states have laws allowing schools to provide ‘undesignated’ asthma medications during emergencies, Illinois is the first state to fund such an effort.

“We applaud the State of Illinois for prioritizing the health of school children and not allowing asthma to interrupt a child’s education,” said Joel Africk, RHA President & CEO. “This funding will help the thousands of Illinois students with asthma stay in school and take some of the burden off parents.”

“This is the very type of system change that positions Illinois to not only improve and save lives but also to be a clear leader in innovative student health solutions. We are grateful and honored to be a part of this work,” said Chris Martinez, Executive Director of Asthma & Allergy Foundation of America – MidStates Chapter.

A 2018 Illinois state law allows schools to keep their own supply of asthma rescue medications on hand for emergencies.  Previously, only individuals with an asthma diagnosis and prescriptions in their own name were permitted to obtain asthma rescue medications.

Asthma episodes are the number one reason for U.S. school absences because of a chronic disease. The CDC estimates that more than 4 million school-aged U.S. children have asthma. And yet, only 17 states allow schools (not just the students with asthma) to carry a supply of emergency asthma medicine at school.



About Respiratory Health Association

Respiratory Health Association has been a local public health leader in Illinois since 1906, focusing on lung health and clean air issues. RHA works to prevent lung disease, promote clean air, and help people live better through education, research, and policy change. As a policy leader, we have been one of the state’s leading advocates for federal oversight of tobacco and vaping products, smoke-free laws, Tobacco 21, and other tobacco product policies. RHA is dedicated to improving asthma management among children and their adult caregivers. Our school-based asthma management education programs are well-established and supported by research. To date, RHA has educated more than 14,000 students with asthma through Fight Asthma Now© and 30,000 adult caregivers through Asthma Management. For more information, visit resphealth.org.


About Asthma and Allergy Foundation

Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and reducing the burden of disease for people with asthma, allergies and related conditions through research, education, advocacy, and support. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of local chapters and affiliated support groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the only asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit: aafa.org

Meenal B. Patwardhan, MD, MHSA, Joins RHA Board of Directors

August 30, 2023 – Chicago, IL – Respiratory Health Association is proud to announce the election of Dr. Meenal B. Patwardhan, MD, MHSA, to its Board of Directors. Dr. Patwardhan’s extensive experience in academia, evidence-based practice, healthcare policy, as well as her leadership in the pharmaceutical industry and expertise in clinical research make her a valuable addition to the Board. Dr. Patwardhan’s appointment reinforces RHA’s commitment to excellence, innovation, and collaboration. Her leadership and strategic insights will play a crucial role in shaping the organization’s future initiatives and driving positive change in the field of lung health.

“As a member of the RHA Board of Directors, I look forward to enabling rigorous research and policy-making that will positively impact the lives of so many patients, like myself, who deal with lung conditions.”

“Dr. Patwardhan’s clinical expertise and leadership is a welcome addition to RHA’s Board of Directors,” said Joel Africk, RHA President and CEO. “We are excited to work with her in our ongoing fight against lung disease to support families, patients, and caregivers.”

Dr. Patwardhan brings a wealth of knowledge and a proven track record of success in various leadership roles. With over 15 years of experience in the pharmaceutical industry, including positions at Abbott/AbbVie, she has demonstrated her ability to lead and motivate large national and international teams. Her expertise in evidence-based medicine, outcomes research, and healthcare decision-making will be instrumental in shaping the strategic direction of RHA.

Additionally, Dr. Patwardhan’s tenure as Adjunct Associate Professor of Medicine at Duke University Medical Center highlights her dedication to education and research. She has contributed significantly to the field of medicine through her research endeavors, clinical trial design, and implementation of evidence-based practices.

Constellation Executive Dwayne Pickett Joins RHA Board of Directors

August 28, 2023 – Chicago, IL – Respiratory Health Association is pleased to announce the appointment of Dwayne Pickett to the board of directors. As a member of the Board of Directors, Dwayne will help guide the strategic direction of RHA and promote corporate engagement. His commitment to excellence, innovation, and community engagement makes him a valuable addition to the board.

“Seeing the devastating effects of lung disease on my own family has driven my passion for clean air and respiratory health in my personal life and in my work,” Pickett said. “I’m honored to join RHA’s board and continue the Association’s long history of successful advocacy and programming to make sure that all of our communities breathe easier.”

“Dwayne’s impressive background and extensive experience in energy policy and regulatory solutions bring a unique perspective on strategy development, team leadership, and stakeholder engagement to the RHA Board,” said RHA President and CEO Joel Africk.

Dwayne currently serves as Vice President of Clean Hydrogen Market Development at Constellation, the nation’s largest producer of carbon-free energy. He previously served in various roles at the Exelon Corporation. In addition, he has been an active health advocate, previously serving as an RHA Associate Board Member and other local nonprofits.

Respiratory Health Association Statement on EPA Decision to Delay Changes to Ozone Health Standard

August 21, 2023 – Chicago, IL – Under the guise of ‘needs more study’ the U.S. Environmental Protection Agency (EPA) today made a decision that ensures Americans will continue to breathe more dangerous ozone smog for many years to come. Rather than proposing a tighter ozone health standard early next year as expected, it has now halted any improvement and deferred further action until 2025 or later.

Scientists officially advising EPA on its air standards made it abundantly clear, based on scientific information that was available years ago, that the current health standard is too weak, does not protect vulnerable groups, and should be strengthened to 55-60 parts per billion (ppb) from the current 70 ppb.

“EPA’s decision will hurt the millions of people who disproportionately suffer the health impacts of poor air quality,” said Joel Africk, RHA President and CEO. “Respiratory Health Association will continue to fight for healthy lungs and clean air for all, especially for the young, seniors, and people living with lung and heart disease and other chronic medical conditions.”

Illinois records ozone smog levels at 33 locations around the state. Even using the inadequate existing ozone health standard set back in 2015, all of those air quality monitoring stations have seen multiple days this year where caustic ozone gas levels exceeded national health standards. Some monitoring stations in the Chicago region saw 20 such days so far this summer.

EPA is also reviewing the adequacy of the fine particle “soot” health standard and, barring any reversal there, is still expected to announce a final decision by the end of this year on the need to reduce deadly fine particles in the air from fossil fuel power plants and motor vehicles.

Lockton Executive Joshua Luther Joins RHA Board of Directors

August 18, 2023 – Chicago, IL – Respiratory Health Association is proud to announce the election of Joshua Luther to the board of directors. Throughout his career at Lockton Companies, Joshua has held various client account team roles, providing him with a deep understanding of client service and the execution of strategic goals. As a member of the Board of Directors, Joshua will play a crucial role in guiding the strategic direction of RHA and championing initiatives that drive increased collaboration with the corporate community.

“As a member of the RHA Board of Directors, I am looking forward to creating and enhancing strong collaborations between RHA and the corporate community. Additionally, this important role allows me to honor my father, who lost his battle with lung cancer in 2009.”

“We are excited for Joshua to bring his energy and insights from leading corporate teams to RHA’s board,” said Joel Africk, RHA President and CEO. “His enthusiasm brings renewed vigor to our efforts to fight for healthy lungs and clean air for all.”

With over 20 years of experience in property and casualty insurance and risk management consulting, Joshua brings a wealth of expertise and leadership to the board. As the Growth & Operations Director and a member of the Executive Committee for the Lockton Midwest Series, he has demonstrated his strategic vision and exceptional ability to drive growth and implement effective people initiatives.

Dr. M. Bradley Drummond Receives 2023 Solovy Award for COPD Research

July 18, 2023 – Chicago, IL – Respiratory Health Association (RHA) is pleased to name M. Bradley Drummond, MD, MHS, the recipient of the 2023 Solovy Award for Advancement in COPD. Dr. Drummond is a distinguished, board-certified pulmonary and critical care physician at the University of North Carolina School of Medicine.

The Solovy Award was established in memory of Mr. Jerold Solovy by his wife, Kathleen Hart Solovy, and funded by the Kathleen Hart Solovy and Jerold S. Solovy Endowment for COPD. This award aims to reduce the burden of chronic obstructive pulmonary disease (COPD) and inspire innovation among lung health researchers.

Upon receiving the Solovy Award, Dr. Drummond will be granted $20,000 to further his COPD research endeavors. This funding will allow him to pursue innovative approaches and breakthroughs that will positively impact the lives of those affected by COPD.

“I have dedicated my career to COPD research as a direct result of my personal experiences caring for patients with COPD. I know what this disease does to people, and these experiences keep me motivated to make discoveries to help those impacted by COPD.” Drummond stated. “This perspective makes the Solovy award, coming from a patient and family impacted by COPD, truly special to me.”

Dr. Drummond is renowned for his expertise in COPD, alpha-1 antitrypsin deficiency, and smoking cessation. He has dedicated his career to unraveling the mechanisms underlying chronic lung disease development and finding innovative solutions for at-risk individuals and those already diagnosed with COPD. As a clinical and translational researcher, Dr. Drummond has focused on characterizing the intricate processes involved in the development of chronic lung disease in high-risk populations. With expertise in epidemiology and clinical trials design, he has shed light on patterns and risk factors for lung function progression in smokers and individuals living with HIV. He also characterizes the longitudinal impact of smoking, HIV infection and tobacco dependence on long-term outcomes related to chronic obstructive pulmonary disease.

“Millions of individuals and their families around the world battle COPD every day,” Drummond stated. “It is their courage and resilience in the face of this insidious disease that fuels my determination to find better treatments, improve patient care, and ultimately discover a cure.”

Dr. Drummond’s projects include a groundbreaking study supported by the National Heart, Lung, and Blood Institute (NHLBI), investigating the role of nasal mucosal immunity and microbiome in controlling COPD progression. He is also actively involved in the Subpopulations and intermediate outcome measures in COPD study (SPIROMICS). In his role as the director of the UNC Obstructive Lung Diseases Clinical and Translational Research Center, Dr. Drummond oversees several clinical research studies, collaborating with NIH and industry sponsors. His leadership and expertise have propelled advancements in COPD research, paving the way for improved treatments and patient care.

“We are excited to recognize Dr. Drummond for his work on behalf of COPD patients and look forward to following his research efforts,” said Joel Africk, RHA’s President and Chief Executive Officer. “COPD has claimed too many of our family members, friends, and colleagues. We are reminded that funding for COPD research is much less than other common chronic diseases.”

Each year Respiratory Health Association awards early-stage research grants to promising projects covering lung diseases such as lung cancer, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). Learn more about RHA’s research program and funding opportunities at RespHealth.org/Research.


About Respiratory Health Association

RHA has been a local public health leader in Chicago since 1906. RHA works to prevent lung disease, promote clean air, and help people live better through education, research, and policy change. To learn more, visit www.resphealth.org.

About the University of North Carolina Department of Medicine

The UNC Department of Medicine represents 12 medicine subspecialties. We train physicians for meaningful and impactful careers, pursue discoveries that advance science, and aim to provide expert, compassionate care to everyone we serve. Our innovative training curriculum prepares physicians to thrive in the ever-changing health care environment. Our research helps shape how we understand and treat disease. And our clinicians collaborate across specialties to provide truly outstanding clinical care.